Skip to content
Research/Peptides/Follistatin 315

Follistatin 315

FST315. 315-amino acid glycoprotein. Inhibits myostatin and activin A. Promotes muscle growth and fat reduction. Myostatin inhibitor, anabolic.

Intelligence Profile

Science

Mechanism of Action

Based on the limited evidence provided, follistatin 315's mechanism of action centers on its role as an antagonist of certain growth factors, though the specific molecular details for this variant are not well-characterized in the available research.

Primary Mechanism:
Follistatin proteins function by binding to and neutralizing members of the TGF-β superfamily, particularly activin and myostatin. While the evidence doesn't specifically detail follistatin 315's mechanism, research on related follistatin variants suggests it likely works by:

  • Binding to activin and myostatin with high affinity
  • Preventing these growth factors from interacting with their cellular receptors
  • Blocking downstream signaling pathways that normally limit muscle growth

Physiological Effects:
The available evidence demonstrates several physiological outcomes that suggest follistatin 315's mechanism involves multiple pathways:

Musculoskeletal System: One study showed that follistatin-induced muscle growth altered bone geometry in young adult male mice, indicating the compound affects both muscle tissue directly and bone indirectly through mechanical loading or paracrine signaling.

Cellular Processes: Research indicates follistatin affects migration, vascularization, and osteogenesis in laboratory settings, and promotes bone repair in living organisms. This suggests the mechanism extends beyond simple muscle growth to include effects on:

  • Cell migration and tissue repair
  • Blood vessel formation
  • Bone formation processes

Signaling Pathways: Evidence shows that activin B (a target of follistatin) can induce non-canonical SMAD1/5/8 signaling through BMP receptors, particularly in liver cells. This suggests follistatin's mechanism may involve modulating multiple signaling cascades beyond the classical activin/myostatin pathways.

Evidence Limitations:
The provided research does not contain detailed molecular studies specifically examining follistatin 315's binding kinetics, receptor interactions, or precise signaling mechanisms. Most studies focus on functional outcomes rather than mechanistic details, and some examine different follistatin variants (such as follistatin 344). The exact pharmacokinetic properties and tissue-specific mechanisms of follistatin 315 remain poorly characterized in the available literature.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.